<DOC>
	<DOCNO>NCT01008462</DOCNO>
	<brief_summary>This phase II trial study autologous peripheral blood stem cell transplant follow donor bone marrow transplant treat patient high-risk Hodgkin lymphoma , non-Hodgkin lymphoma , multiple myeloma , chronic lymphocytic leukemia . Autologous stem cell transplantation use patient 's stem cell cause graft versus host disease ( GVHD ) low risk death , minimize number cancer cell . Peripheral blood stem cell ( PBSC ) transplant use stem cell patient donor may able replace immune cell destroy chemotherapy . These donated stem cell may help destroy cancer cell . Bone marrow transplant know nonmyeloablative transplant use stem cell haploidentical family donor . Autologous peripheral blood stem cell transplant follow donor bone marrow transplant may work well treat patient high-risk Hodgkin lymphoma , non-Hodgkin lymphoma , multiple myeloma , chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Autologous Peripheral Blood Stem Cell Transplant Followed Donor Bone Marrow Transplant Treating Patients With High-Risk Hodgkin Lymphoma , Non-Hodgkin Lymphoma , Multiple Myeloma , Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I. Event-free survival ( EFS ) 1-year autograft . SECONDARY OBJECTIVES : I. Relapse rate 1-year autograft . II . Overall survival ( OS ) 1-year autograft . III . Incidence grade II-IV acute GVHD chronic extensive GVHD . IV . Non-relapse mortality ( NRM ) 200 day 1 year allograft . V. Donor engraftment day +84 . VI . Incidence infection . OUTLINE : CONDITIONING REGIMEN 1 ( lymphoma , Waldenstrom macroglobulinemia , chronic lymphocytic leukemia [ CLL ] dose limit radiation significant comorbidities : Patients receive cyclophosphamide intravenously ( IV ) day -6 -5 . Patients undergo high-dose total body irradiation ( TBI ) twice daily ( BID ) day -3 -1 . CONDITIONING REGIMEN 2 ( lymphoma , Waldenstrom Macroglobulinemia , CLL , prior dose-limiting radiation , significant comorbidities ) : Patients receive carmustine IV day -7 , etoposide IV BID day -6 -3 , cytarabine IV BID day -6 -3 , melphalan IV day -2 . CONDITIONING REGIMEN 3 ( multiple myeloma plasma cell leukemia , significant renal insufficiency significant comorbidities ) : Patients receive high-dose melphalan IV day -2 . CONDITIONING REGIMEN 4 ( multiple myeloma plasma cell leukemia , significant renal insufficiency significant comorbidities ) : Patients receive lessen dose melphalan IV day -2 . PBSC TRANSPLANTATION : All patient undergo autologous PBSC transplantation day 0 . WAITING INTERVAL : Between 40 120 day . NONMYELOABLATIVE CONDITIONING REGIMEN : Patients receive fludarabine phosphate IV daily ( QD ) day -6 -2 cyclophosphamide IV QD day -6 -5 day 3 . Patients infuse donor 's peripheral blood stem cell additionally receive cyclophosphamide IV day 4 . Patients undergo low-dose TBI day -1 . ALLOGENEIC BONE MARROW TRANSPLANTATION : Patients undergo donor bone marrow transplantation day 0 . GRAFT VERSUS HOST DISEASE PROPHYLAXIS : Beginning day 4 , patient receive tacrolimus orally ( PO ) IV taper begin day 86 graft-versus-host disease . Patients also receive mycophenolate mofetil PO thrice daily ( TID ) day 4 - 35 . PERIPHERAL BLOOD COUNT SUPPORT : Patients receive filgrastim ( G-CSF ) IV subcutaneously ( SC ) begin day 4 continue till blood count recover . ALLOGENEIC PERIPHERAL BLOOD MONONUCLEAR CELLS ( PBMC ) TRANSPLANTATION : Patients undergo donor PBMC transplantation day 0 . GRAFT VERSUS HOST DISEASE PROPHYLAXIS : Beginning day 5 , patient receive tacrolimus orally ( PO ) IV taper begin day 86 graft-versus-host disease . Patients also receive mycophenolate mofetil PO thrice daily ( TID ) day 5 - 35 . PERIPHERAL BLOOD COUNT SUPPORT : Patients receive filgrastim IV SC begin day 5 continue till blood count recover . After completion study treatment , patient follow annually 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Leukemia , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic , T-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Nitrogen Mustard Compounds</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<criteria>Must capacity give inform consent Detectable tumor prior mobilization regimen Patients human leukocyte antigen ( HLA ) match unrelated donor search could initiate complete due insurance reason , concern rapidly progressive disease , and/or discretion attend physician eligible protocol Patients store autologous stem cell allow Stem cell identical donor could use autologous hematopoietic cell transplant ( HCT ) Marrow prefer source stem cell HLAhaploidentical donor , however , peripheral blood mononuclear cell ( PBMC ) could use stem cell source , clearance Fred Hutchinson Cancer Research Center ( FHCRC ) principal investigator , case difficulty contraindication bone marrow harvest donor Crossover tandem autologousallogeneic research protocol ( # 1409 appropriate protocol ) allow suitable HLAmatched relate unrelated donor identify receive allogeneic transplantation patient meet eligibility criterion subsequent study Crossover tandem autologousallogeneic research protocol ( # 1409 appropriate protocol ) allow patient loses suitable HLAmatched relate unrelated donor available HLAhaploidentical donor receive allogeneic transplantation patient meet eligibility criterion subsequent study Lymphoma : patient Diagnosis nonHodgkin lymphoma ( NHL ) Hodgkin 's lymphoma ( HL ) , histological grade Refractory relapse disease standard chemotherapy High risk early relapse follow autograft alone Waldenstrom 's macroglobulinemia : must fail 2 course therapy CLL : Patients either : Diagnosis Tcell CLL Tcell prolymphocytic leukemia ( PLL ) fail initial chemotherapy , patient T cell CLL PLL Diagnosis Bcell CLL , Bcell small lymphocytic lymphoma , Bcell CLL progress PLL either : 1 . Failed meet National Cancer Institute ( NCI ) Working Group criteria complete partial response therapy regimen contain fludarabine ( another nucleoside analog , e.g . 2chlorodeoxyadenosine [ CDA ] , pentostatin ) experience disease relapse within 12 month complete therapy regimen contain fludarabine ( another nucleoside analog ) 2 . Failed aggressive chemotherapy regimen , fludarabine , cyclophosphamide rituximab ( FCR ) , time point 3 . Have `` 17p deletion '' cytogenetic abnormality relapse time point initial chemotherapy Harvesting criterion autologous HCT : Previously collect PBMC may use Circulating CLL cell &lt; 5000 Marrow involvement CLL cell &lt; 50 % Multiple myeloma ( MM ) : patient Have receive induction therapy minimum 4 cycle In addition , patient must meet least one follow criterion IIX ( IVII time diagnosis preautograft ) : Any abnormal karyotype metaphase analysis except isolate ( 11,14 ) , Fluorescent situ hybridization ( FISH ) translocation 4:14 , FISH translocation 14:16 , FISH deletion 17p , Beta2 ( B2 ) microglobulin &gt; 5.5 mg/ml , Cytogenetic hypodiploidy Plasmablastic morphology ( &gt; = 2 % ) Recurrent nonresponsive ( less partial remission [ PR ] ) MM least two different line conventional chemotherapy Progressive MM previous autograft ( provide store autologous cluster differentiation [ CD ] 34 cell available ) Plasma cell leukemia : induction chemotherapy DONOR : Related donor genotypically identical one HLA haplotype may mismatch HLAA , B , C DRB1 locus unshared haplotype exception single HLAA , B C allele mismatch DONOR : Marrow prefer source stem cell HLAhaploidentical donor , however PBMC could use stem cell source , clearance FHCRC principal investigator , case difficulty contraindication bone marrow harvest donor DONOR : In case PBMC use stem cell source , ability donor &lt; 18 year age undergo apheresis without use vascular access device ; vein check must perform verified apheresis nurse prior arrival Seattle Cancer Care Alliance ( SCCA ) DONOR : Age &gt; = 12 year age Life expectancy severely limited disease malignancy Seropositive human immunodeficiency virus Female patient pregnant breastfeed Fertile men woman unwilling use contraceptive technique 12 month follow treatment Patients available HLA match related donor Central nervous system ( CNS ) involvement disease refractory intrathecal chemotherapy Patients active nonhematological malignancy ( except nonmelanoma skin cancer ) nonhematological malignancy ( except nonmelanoma skin cancer ) render evidence disease , great 20 % chance disease recurrence within 5 year This exclusion apply patient nonhematologic malignancy require therapy Patients fungal infection radiological progression receipt amphotericin B active triazole great 1 month Symptomatic coronary artery disease ejection fraction &lt; 40 % cardiac failure require therapy ( , unable obtain ejection fraction , shorten fraction &lt; 26 % ) ; ejection fraction require patient history anthracyclines history cardiac disease ; patient shorten fraction &lt; 26 % may enrol approve cardiologist Corrected diffusion capacity lung carbon monoxide ( DLCO ) &lt; 50 % predict , forced expiratory volume one second ( FEV1 ) &lt; 50 % predict , and/or receive supplementary continuous oxygen ; FHCRC principal investigator ( PI ) study must approve enrollment patient pulmonary nodule Patient clinical laboratory evidence liver disease evaluate cause liver disease , clinical severity term liver function , bridge fibrosis , degree portal hypertension ; patient exclude he/she find fulminant liver failure , cirrhosis liver evidence portal hypertension , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evince prolongation prothrombin time , ascites related portal hypertension , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL , symptomatic biliary disease Karnofsky score &lt; 50 % adult patient Lansky playperformance score &lt; 40 pediatric patient Patient poorly control hypertension despite multiple antihypertensive DONOR : Donorrecipient pair HLAmismatch hostversusgraft ( HVG ) direction DONOR : Infection human immunodeficiency virus ( HIV ) DONOR : Weight &lt; 20 kg DONOR : A positive antidonor cytotoxic crossmatch</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>